Cargando…

Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations

Proteolysis targeting chimeric molecule ARV 825 causes ubiquitination of bromodomains resulting in their efficient degradation by proteasome activity. Bromodomain degradation down-regulates MYC transcription contributing to growth inhibition of various human cancers. We examined the therapeutic pote...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Su Lin, Damnernsawad, Alisa, Shyamsunder, Pavithra, Chng, Wee Joo, Han, Bing Chen, Xu, Liang, Pan, Jian, Pravin, Dakle Pushkar, Alkan, Serhan, Tyner, Jeffrey W., Koeffler, H. Phillip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545861/ https://www.ncbi.nlm.nih.gov/pubmed/30606790 http://dx.doi.org/10.3324/haematol.2018.201483

Ejemplares similares

Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor
por: Lim, Su-Lin, et al.
Publicado: (2020)

THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors
por: Shyamsunder, Pavithra, et al.
Publicado: (2022)

CARD10, a CEBPE target involved in granulocytic differentiation
por: Shyamsunder, Pavithra, et al.
Publicado: (2018)

ZRSR1 co-operates with ZRSR2 in regulating splicing of U12-type introns in murine hematopoietic cells
por: Madan, Vikas, et al.
Publicado: (2021)

Dissecting the role of SWI/SNF component ARID1B in steady-state hematopoiesis
por: Madan, Vikas, et al.
Publicado: (2023)

Chromatin remodeling mediated by ARID1A is indispensable for normal hematopoiesis in mice
por: Han, Lin, et al.
Publicado: (2019)

Proteolysis Targeting Chimeric Molecules: Tuning Molecular Strategies for a Clinically Sound Listening
por: Pedrucci, Federica, et al.
Publicado: (2022)

Metabolic Vulnerabilities in Multiple Myeloma
por: Lim, Julia S. L., et al.
Publicado: (2022)

Identification of somatic alterations in lipoma using whole exome sequencing
por: Kanojia, Deepika, et al.
Publicado: (2019)

Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer
por: Chan, Daniel, et al.
Publicado: (2013)

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2014)

Implications of Heterogeneity in Multiple Myeloma
por: de Mel, Sanjay, et al.
Publicado: (2014)

MicroRNA: Important Player in the Pathobiology of Multiple Myeloma
por: Bi, Chonglei, et al.
Publicado: (2014)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

Vγ9Vδ2 T cells expressing a BCMA—Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth
por: Zhang, Xi, et al.
Publicado: (2022)

CAR T-cell therapy in multiple myeloma: more room for improvement
por: Teoh, Phaik Ju, et al.
Publicado: (2021)

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2022)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

A genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways that mediate resistance to sorafenib in acute myeloid leukemia
por: Damnernsawad, Alisa, et al.
Publicado: (2020)

STAT3: A Promising Therapeutic Target in Multiple Myeloma
por: Chong, Phyllis S. Y., et al.
Publicado: (2019)

Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma
por: Xiong, Sinan, et al.
Publicado: (2021)

Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas
por: Jeitany, Maya, et al.
Publicado: (2020)

Potential Clinical Application of Genomics in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2018)

Targeting NF-κB Signaling for Multiple Myeloma
por: Wong, Ada Hang-Heng, et al.
Publicado: (2020)

ASXL2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion
por: Madan, Vikas, et al.
Publicado: (2018)

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2019)

Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence
por: Abid, Muhammad Bilal, et al.
Publicado: (2016)

Genomic characterization of functional high-risk multiple myeloma patients
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2022)

A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma
por: Chung, Tae-Hoon, et al.
Publicado: (2013)

Tumor-Associated Macrophages and Related Myelomonocytic Cells in the Tumor Microenvironment of Multiple Myeloma
por: Wang, Samuel S. Y., et al.
Publicado: (2022)

LPS independent activation of the pro-inflammatory receptor Trem1 by C/EBPε in granulocytes
por: Suh, Hyung C., et al.
Publicado: (2017)

Proteolysis and antigen presentation by MHC class II molecules
por: Bryant, Paula Wolf, et al.
Publicado: (2002)

IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification
por: Teoh, Phaik Ju, et al.
Publicado: (2020)

Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination
por: Li, Zhenhai, et al.
Publicado: (2020)

P833: MARCH5 AS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA
por: Bashiri, Hamed, et al.
Publicado: (2023)

Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT)
por: Kusuma, Frances Karla, et al.
Publicado: (2023)

Chimeric antigen receptor T cell therapy for multiple myeloma
por: Hasegawa, Kana, et al.
Publicado: (2019)

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
por: Hosen, Naoki
Publicado: (2019)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy for multiple myeloma
por: Wang, Zehua, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8i6ceskpa7vpbtudt5dimjq1at